Guggenheim Forecasts Strong Price Appreciation for Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price objective upped by analysts at Guggenheim from $89.00 to $97.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim‘s target price indicates a potential upside of 41.40% from the stock’s previous close.

Several other research analysts also recently weighed in on TARS. The Goldman Sachs Group began coverage on Tarsus Pharmaceuticals in a report on Thursday, September 24th. They issued a “buy” rating and a $116.00 price target for the company. Mizuho decreased their price objective on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. HC Wainwright lifted their price objective on Tarsus Pharmaceuticals from $88.00 to $106.00 and gave the company a “buy” rating in a research report on Wednesday. Barclays started coverage on Tarsus Pharmaceuticals in a research note on Wednesday, September 16th. They issued an “overweight” rating and a $110.00 target price for the company. Finally, Jefferies Financial Group increased their target price on Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.57.

Tarsus Pharmaceuticals Trading Up 1.6%

Shares of NASDAQ TARS traded up $1.08 during midday trading on Thursday, reaching $68.60. 1,088,955 shares of the stock were exchanged, compared to its average volume of 895,567. The stock has a 50 day moving average price of $74.99 and a 200-day moving average price of $67.82. The company has a current ratio of 3.20, a quick ratio of 3.17 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $3.38 billion, a P/E ratio of -4.52 and a beta of 0.34. Tarsus Pharmaceuticals has a 52-week low of $53.89 and a 52-week high of $91.53.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($14.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.46) by ($12.94). Tarsus Pharmaceuticals had a negative net margin of 7.67% and a negative return on equity of 13.53%. The firm had revenue of $194.57 million for the quarter, compared to analysts’ expectations of $187.83 million. Equities research analysts expect that Tarsus Pharmaceuticals will post -12.10 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Elizabeth Lin sold 10,773 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $87.50, for a total transaction of $942,637.50. Following the completion of the sale, the insider directly owned 2,547 shares of the company’s stock, valued at $222,862.50. The trade was a 80.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director William J. Phd Link sold 12,500 shares of the business’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $78.38, for a total transaction of $979,750.00. Following the sale, the director directly owned 94,487 shares of the company’s stock, valued at $7,405,891.06. This represents a 11.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 48,031 shares of company stock valued at $4,004,227. Insiders own 9.64% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in TARS. Eurizon Capital SGR S.p.A. acquired a new position in Tarsus Pharmaceuticals in the third quarter valued at $35,000. Parallel Advisors LLC increased its stake in Tarsus Pharmaceuticals by 139.2% during the first quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock worth $35,000 after acquiring an additional 291 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in shares of Tarsus Pharmaceuticals by 851.6% in the 3rd quarter. Farther Finance Advisors LLC now owns 590 shares of the company’s stock worth $46,000 after purchasing an additional 528 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of Tarsus Pharmaceuticals by 367.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 710 shares of the company’s stock worth $50,000 after purchasing an additional 558 shares during the period. Finally, Covestor Ltd raised its holdings in shares of Tarsus Pharmaceuticals by 40.0% in the 3rd quarter. Covestor Ltd now owns 1,095 shares of the company’s stock worth $86,000 after purchasing an additional 313 shares during the period. 90.01% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Recent coverage highlights record Q3 sales and a raised revenue outlook, supporting the view that commercial momentum is improving. The reported $194.57 million in quarterly revenue also exceeded the cited consensus estimate of $187.83 million. Tarsus Pharmaceuticals Could Be 31% Undervalued Following Record Q3 Sales
• Positive Sentiment: Guggenheim raised its price target to $97 from $89 and maintained a Buy rating. HC Wainwright also kept its Buy rating and $106 target, while raising its FY2027–FY2030 earnings forecasts, suggesting greater confidence in longer-term profitability. Tarsus Pharmaceuticals Stock Gets Price Target Increase from HC Wainwright
• Neutral Sentiment: Tarsus plans to participate in upcoming investor conferences. The announcement may provide opportunities for investor updates but does not disclose a new business or clinical development. Tarsus to Participate in Upcoming Investor Conferences
• Negative Sentiment: HC Wainwright cut its Q4 2026 EPS forecast to a loss of $0.55 from a loss of $0.14, and reduced its FY2026 estimate to a loss of $15.85 from $2.25. Separately, Tarsus reported a Q3 loss of $14.40 per share, substantially wider than the cited $1.46 consensus loss. These figures raise concern about near-term costs and profitability despite revenue growth.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye diseases with significant unmet medical needs. The company’s portfolio is centered on therapies designed to address conditions affecting the ocular surface and eyelids.

Tarsus’ lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, an inflammatory eyelid condition associated with an infestation of Demodex mites.